Clinical trials: Oncologic Patients
Renal Cell Carcinoma
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts
- Trial name
- NCT05725421
- Testing
- Donor Radical and Partial Nephrectomy, Kidney Transplantation, Laparoscopic Radical Nephrectomy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Solid, Liquid, Central Nervous System Tumors
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
The development of next generation sequencing (NGS) techniques, including whole genome (WGS), exome (WES) and RNA sequencing has revolutionized the ability of investigators to query the molecular mechanisms underlying tumor…
- Trial name
- NCT02530658
- Testing
- Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- St. Jude Children's Research Hospital
Pancreatic Cancer, Metastatic Pancreatic Cancer
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
This study will compare the anti-tumor efficacy of apricoxib and gemcitabine/erlotinib with placebo and gemcitabine/erlotinib in patients with advanced pancreatic cancer.
- Trial name
- NCT00709826
- Testing
- gemcitabine, Erlotinib, apricoxib
- Where
- 39 sites in United States
- Volunteers
- 109 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Metastatic Colorectal Cancer (mCRC)
Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)
The primary objective of this trial is to compare the effects of 18 weeks structured exercise training versus on control on healt-related quality of life in patients with mCRC undergoing first-line chemotherapy.
- Trial name
- REACH (NCT06938971)
- Testing
- Exercise training
- Where
- 4 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Non-Hodgkin Lymphoma
PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care
The main objective of the proposed study is to assess the effectiveness, feasibility and costs of a tailored strategy (developed in accordance with the barriers found and current practice) to improve care for patients with…
- Trial name
- NCT01562509
- Testing
- Implementation tools, Standard intervention
- Where
- Netherlands
- Volunteers
- 418 people
- Sponsor
- Radboud University Medical Center
Medication Reconciliation
Medication Reconciliation in Oncologic Patients
To improve medication reconciliation in oncologic patients in healthcare transitions through an alliance between a Cancer Institute and the community pharmacies and a new integrated IT platform.
- Trial name
- PROF2 (NCT04796142)
- Testing
- medication reconciliation
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative…
- Trial name
- NCT01074970
- Testing
- Cisplatin, Rucaparib
- Where
- 27 sites in United States
- Volunteers
- 135 people
- Sponsor
- Hoosier Cancer Research Network
Neoplasms, Ovarian Neoplasms
Biobehavioral Intervention in Gynecologic Oncology Patients
Baseline self-report outcome measures will be completed and additional assessments will occur mid-treatment , post-treatment , 3 months following completion of all sessions, and 6 months following completion of all sessions.
- Conditions
- Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vulva
- Trial name
- NCT02454036
- Testing
- BBI intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Rachel Miller
Solid Tumor
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose…
- Trial name
- NCT04541108
- Testing
- Rilvegostomig, Volrustomig, Sabestomig
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Presage Biosciences
Malignant Neoplasm of Breast, Breast Cancer
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
This study will test the theory that therapy designed for each individual's tumor will improve outcomes over standard of care in a population that needs a better standard.
- Trial name
- NCT02101385
- Testing
- Genomically Directed Monotherapy, Observation/Standard Therapy
- Where
- 29 sites in United States
- Volunteers
- 193 people
- Sponsor
- Bryan Schneider, MD
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Insomnia
Feasibility of Internet Group CBT-I for Gyn Oncology Patients
The goal of this study is to evaluate the feasibility and acceptability of delivering cognitive behavioral therapy for insomnia (CBT-I) to gynecologic cancer patients in an internet-based small-group setting.
- Trial name
- NCT06060158
- Testing
- Cognitive Behavioral Therapy for Insomnia
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Davis
Gynecologic Cancer, Anemia
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
Iron deficiency has been reported in approximately 35% of patients with a gynecologic malignancy. Blood transfusions are known to be immunosuppressive and carry immediate and long-term risks.
- Conditions
- Gynecologic Cancer, Anemia, Iron-deficiency
- Trial name
- FORGE II (NCT05407987)
- Testing
- Ferric derisomaltose
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- AHS Cancer Control Alberta
Gynecologic Cancer, Frailty
Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients
FARGO is a prospective cohort study that aims to determine the performance of preoperative frailty assessment based on the Frailty Phenotype (FP), compared to a perioperative cardiovascular risk assessment based on the…
- Conditions
- Gynecologic Cancer, Frailty, Oncology
- Trial name
- FARGO (NCT05738252)
- Testing
- Clinical Frailty Scale, Frailty Phenotype
- Where
- 4 sites in Canada
- Volunteers
- 280 people
- Sponsor
- Population Health Research Institute
Esophageal Cancer, Gastric Cancer (Diagnosis)
Exercise Training After Upper Gastrointestinal Cancer Surgery
This randomized controlled trial aims to determine the optimal exercise intensity for improving postoperative recovery in patients with upper gastrointestinal cancer.
- Conditions
- Esophageal Cancer, Gastric Cancer (Diagnosis), Upper Gastrointestinal Cancer
- Trial name
- NCT07561840
- Testing
- High-Intensity Interval Training (HIIT), Low-Intensity Continuous Training (LICT)
- Where
- 2 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Kansai Medical University
Oncology, Advance Care Planning
Implementation of Online Advance Care Planning Tool for (Hemato-)Oncological Patients Within the Cancer Network Concord
The aim of this mixed-methods study is to describe both the implementation process and outcomes of the online module Advance Care Plan for (hemato-)oncology patients within the oncology-network CONCORD.
- Conditions
- Oncology, Advance Care Planning, Implementation
- Trial name
- INDEED (NCT06350968)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
Multiple Myeloma
Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma
This study evaluated an individualized, nurse-delivered education program for managing treatment-related symptoms in patients with newly diagnosed multiple myeloma receiving bortezomib for the first time.
- Trial name
- NCT07774988
- Testing
- Individualized Nurse-Delivered Education Program
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- Can Lafci
Hepatitis E Infection, Hepatitis; Epidemic
Hepatitis E Virus Infection in Oncological Patients
The goal of this clinical trial is to investigate the prevalence of hepatitis E infection in oncological patients in a rural region of Germany.
- Conditions
- Hepatitis E Infection, Hepatitis; Epidemic, Oncologic Disorders
- Trial name
- HepE-Onko-BB (NCT06631560)
- Testing
- ELISA testing
- Where
- Germany
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
Empgliflozin Cardioprotective Effect
Cardioprotective Effect of Empagliflozin in Breast Cancer Patients
Background: Doxorubicin (DOX) remains a cornerstone in adjuvant and neoadjuvant therapy for breast cancer, but its utility is hindered by dose-dependent cardiotoxicity.
- Trial name
- NCT07815808
- Testing
- Empagliflozin (EMPA), Metformin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.